With a focus on rare diseases and a pipeline of targeted therapies, this commercial-stage company operates at the intersection of scientific innovation and unmet clinical need. Several recent developments make it a stock worth watching in the current market landscape.
Zevra Therapeutics Inc. (ZVRA) develops treatments for conditions such as idiopathic hypersomnia, narcolepsy, vascular Ehlers-Danlos syndrome, and Niemann-Pick Disease Type C. Its commercial portfolio includes AZSTARYS, approved for attention deficit hyperactivity disorder, and OLPRUVA, indicated for certain urea cycle disorders, both currently available in the U.S.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com